.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,741,268

« Back to Dashboard
Patent 7,741,268 protects GONAL-F RFF REDI-JECT and is included in one NDA.

This patent has thirty patent family members in twenty-nine countries.

Summary for Patent: 7,741,268

Title:Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
Abstract:The invention relates to the field of pharmaceutical formulations of follicle-stimulating hormone (FSH), luteinising hormone (LH), and mixtures of FSH and luteinising hormone (LH), and to methods of producing such formulations. The invention provides a liquid or freeze-dried formulation of FSH, or LH, or FSH and LH comprising a surfactant selected from Pluronic.RTM. F77, Pluronic F87, Pluronic F88 and Pluronic F68.
Inventor(s): Samaritani; Fabrizio (Rome, IT), Donati; Piergiorgio (Morges, CH)
Assignee: Ares Trading S.A. (Aubonne, CH)
Application Number:10/551,840
Patent Claim Types:
see list of patent claims
Composition;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 64th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Emd Serono
GONAL-F RFF REDI-JECT
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021684-001May 25, 2004RXYes7,741,268► subscribeY
Emd Serono
GONAL-F RFF REDI-JECT
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021684-002May 25, 2004RXYes7,741,268► subscribeY
Emd Serono
GONAL-F RFF REDI-JECT
follitropin alfa/beta
INJECTABLE;SUBCUTANEOUS021684-003May 25, 2004RXYes7,741,268► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,741,268

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03100882Apr 02, 2003
03101543May 27, 2003
03101828Jun 20, 2003
PCT Information
PCT FiledApril 02, 2004PCT Application Number:PCT/EP2004/050432
PCT Publication Date:October 14, 2004PCT Publication Number: WO2004/087213

International Patent Family for Patent: 7,741,268

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia1610822► subscribe
Serbia20050737► subscribe
Portugal1610822► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc